Inhaled glucocorticoids (GCs) have revolutionized
|
|
- Virgil Cox
- 6 years ago
- Views:
Transcription
1 Factors Influencing the Responsiveness to Inhaled Glucocorticoids of Patients With Moderate-to-Severe Asthma* An-Soo Jang, MD; June-Hyuk Lee, MD; Sung Woo Park, MD; Young Mok Lee, MD; Soo Taek Uh, MD; Yong-Hoon Kim, MD; and Choon-Sik Park, MD Study objectives: Inhaled glucocorticoids (GCs) are the most effective control therapy for asthma. Although the clinical effects of inhaled GCs vary, there are few data on the differences in the responsiveness of individuals to inhaled GCs. The purpose of this study was to identify those factors that are associated with responsiveness to high-dose inhaled GCs in patients with moderate-to-severe asthma. Design: This study was a prospective analysis. Setting: Outpatient clinics of tertiary hospitals. Patients: Eighty-six adult outpatients with moderate-to-severe asthma. Methods: Eighty-six patients with asthma who had initial FEV 1 values of < 80% predicted after they had received inhaled GCs (fluticasone propionate, 1,000 g/d) for 4 weeks. The primary end points were FEV 1, FEV 1 /FVC ratio, forced expiratory flow (midexpiratory phase), and the score at presentation in the asthma-related quality-of-life questionnaire (AQLQ). Results: The inhalation of GCs for 4 weeks had significant improvements in the FEV 1% predicted and in the AQLQ score compared with the baseline values. Asthmatic patients with responses of > 12% (n 46, 53.4%) in the change in FEV 1 ( FEV 1 [FEV 1 at 4 weeks baseline FEV 1 ]/ baseline FEV 1 100) also had significantly higher proportions of blood eosinophils and lower FEV 1 values (in liters) prior to treatment. The change in FEV 1 values correlated with the number of sputum eosinophils prior to GC inhalation (r 0.242; p < 0.05) and correlated inversely with the FEV 1 percent predicted values prior to GC inhalation (r 0.462; p < 0.001). Conclusion: The FEV 1 percent predicted and the blood and sputum eosinophil levels prior to GC inhalation are associated with the responsiveness to inhaled GCs in patients with moderate-tosevere asthma. (CHEST 2005; 128: ) Key words: asthma; FEV 1 ; glucocorticoid; inhalation; responsiveness Abbreviations: AHR airway hyperresponsiveness; AQLQ asthma-related quality-of-life questionnaire; BDP beclomethasone propionate; FEF forced expiratory flow; FEF 25 75% forced expiratory flow midexpiratory phase; FP fluticasone propionate; GC glucocorticoid; PC 20 provocative concentration of a substance causing a 20% fall in FEV 1 Inhaled glucocorticoids (GCs) have revolutionized the treatment of asthma and have become the mainstay of therapy for patients with chronic asthma. 1 3 Physiology, airway inflammation, and airway remodeling in asthma patients are interrelated and improved with GC therapy. Early and long-term *From the Asthma and Allergy Research Group (Drs. Jang, J.-H. Lee, S.W. Park, and C.-S. Park), Division of Allergy and Respiratory Medicine, Soonchunhyang University Hospital, Bucheon, Republic of Korea; and Asthma and Allergy Research Group (Drs. Y.M. Lee, Uh, and Kim), Division of Allergy and Respiratory Medicine, Soonchunhyang University Hospital, Seoul, Republic of Korea. Supported by a grant from the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (01-PJ3- PG6 01GN04 003). intervention with GC therapy is needed, even in patients with relatively mild asthma. 4 According to asthma management guidelines, 3 patients with moderate persistent asthma should begin inhaled GC therapy with a dose of 400 to 800 g of budesonide or its equivalent; treatment at this dosage should Manuscript received March 15, 2004; revision accepted December 1, Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( org/misc/reprints.shtml). Correspondence to: Choon-Sik Park, MD, Division of Allergy and Respiratory Medicine, Department of Internal Medicine, Soonchunhyang University Hospital, 1174, Jung-dong, Wonmi-gu, Bucheon-si, Gyeonggido , Republic of Korea; schalr@schbc.ac.kr 1140 Clinical Investigations
2 continue for 3 months, which is the amount of time required to obtain maximal benefit from the inhaled steroid. The dosage of inhaled GCs may then be reduced according to a simple step-down regimen. In some patients, the initial dose of steroid may be too low, making it necessary to increase the dose. In patients with severe persistent asthma, a budesonide dosage of 800 g/d may be needed, or therapy with oral steroids may be required in order to obtain initial control of the asthma. A small percentage of asthmatic patients have symptoms that are severe enough to require high doses of GCs in order to establish maximal lung function. 5 In a previous study, a change in the FEV 1 became apparent by 4 weeks of treatment with inhaled GCs and peaked by 8 weeks of treatment. 6 However, the data in that study were not based on the changes in FEV 1 for individual patients but on averages of the overall FEV 1 values. Although variable responses to inhaled GC therapy are expected among asthma patients, short-term cross-sectional data on their effects on factors that determine the outcome of inhaled GC treatment are rare. Therefore, the aims of this study were as follows: (1) to estimate individual responsiveness in terms of pulmonary function and asthma symptoms after 4 weeks of treatment with the maximum recommended dose of an inhaled GCs (1,000 g fluticasone propionate [FP]) in patients with moderate-tosevere asthma; (2) to classify each patient as a responder or nonresponder; and (3) to identify the factors that determine the outcome of inhaled GC treatment. Study Design Materials and Methods On the first day of the study (Fig 1), a clinical history was obtained for each patient using a physician-administered questionnaire. Chest posteroanterior radiography, allergy skin prick tests, and spirometry, including bronchodilator responses after the inhalation of two puffs of 100 g aerosolized albuterol, were performed. The blood and sputum were sampled for differential cell counts. The asthma-related quality-of-life questionnaire (AQLQ) was evaluated at baseline and at 4 weeks of treatment. On the second day, airway hyperresponsiveness (AHR) was measured in patients with FEV 1 values of 70% predicted. The patients were educated visually by a trained nurse as to the use of inhaled GCs until their accuracy scores reached 12 (maximal score, 14). 7 GC inhalation therapy was maintained for 4 weeks. An inhaled GC dose of 1,000 g/d FP was self-administered via a multidose dry-powder inhaler (Diskhaler; GlaxoSmithKline; Research Triangle Park, NC) [two puffs bid]. During the study period, the patients were asked to record their symptom scores and medication. The patients used short-acting bronchodilators as needed. During the study period, patients were switched to combination or add-on therapy in cases of exacerbations, that is, reductions of 12% in AQLQ or FEV 1, anytime that aggravating symptoms developed. The primary end points were changes in basal FEV 1, the FEV 1 /FVC ratio, and the forced expiratory flow, midexpiratory phase (FEF 25 75% ) after active treatment with inhaled GCs. The change in the validated asthma control score was a secondary end point. Subjects Patients with chronic asthma were recruited from the outpatient clinics of Soonchunhyang University Hospital. All of the patients exhibited one or more asthma symptoms, and their physical examinations were compatible with the American Thoracic Society definition of asthma. 8 Each patient showed airway reversibility, as documented by a positive bronchodilator response of a 15% increase in FEV 1 and/or airway hyperreactivity to 10 mg/ml methacholine. 9 The exclusion criteria included duration of asthma of 1 year, acute exacerbated asthma within 4 weeks, history of brittle asthma, atopy to pollens, parenchymal lung disease apparent on chest radiography, diffusing capacity of 80%, previous inhaled steroid or systemic steroid use within the past 4 weeks, and maintenance therapy with theophylline or a leukotriene antagonist. Nineteen of the patients were current smokers, and 20 were ex-smokers who had given up smoking a median of 15 years prior to recruitment into the study. The prospective controlled trial involved 86 patients (mean age, 46 years) with moderate-to-severe persistent asthma according to the Global Initiative for Asthma guidelines. 3 The clinical parameters are summarized in Table 1. Thirty-seven percent of asthmatic patients showed a positive response to the skin test with common inhalant allergens. The change from day 1 to day 28 in FEV 1 ( FEV 1 [FEV 1 at 4 weeks baseline FEV 1 ]/baseline FEV 1 100) following the inhalation of GCs was measured. Responders to the inhaled GC therapy were identified as those patients who demonstrated responses of 12% in FEV 1. During this period, seven asthmatic patients were moved to the combination or add-on therapy because of decreases of 12% in FEV 1 or AQLQ together with symptom aggravation. Those patients were included as nonresponders to the inhaled GC therapy. This study was performed with the approval of the Ethics Committee of the Soonchunhyang University Hospital, and informed written consent was obtained from all of the study subjects. Quality-of-Life Measurement Figure 1. Schematic diagram of study design. The AQLQ was evaluated at baseline and at 4 weeks of treatment using the Korean modification of the Juniper asthma CHEST / 128 / 3/ SEPTEMBER,
3 Table 1 Characteristics in Patients With Asthma Prior to Treatment According to Responsiveness to Inhaled GCs* Characteristics quality-of-life questionnaire. 10 The answers to each question were scored on a 5-point scale, with a score of 1 representing the greatest impairment and a score of 5 representing no impairment (lower AQLQ scores reflect increased impairment). Items were weighted equally and reported as the mean score for each domain (activity limitations, emotions, symptoms, and exposure to environmental stimuli), along with the overall score. Lung Function Tests Baseline measurements of FVC and FEV 1 were obtained in the absence of recent use (ie, within 8 h) of a bronchodilator and were selected according to the American Thoracic Society criteria. 8 Basal and postbronchodilator FEV 1, FVC, and FEF 25 75% were measured between 1:00 pm and 4:00 pm. AHR was measured by methacholine challenge and was expressed as the provocative concentration of a substance causing a 20% fall in FEV 1 (PC 20 ) in noncumulative units. 11 Sputum Examination Sputum was induced using an isotonic saline solution that contained a short-acting bronchodilator, as described by Norzila et al. 12 Samples were treated within 2hofcollection using the method of Pizzichini et al 13 with a minor modification. Briefly, all of the visible portions with greater solidity were carefully selected and placed in a preweighed Eppendorf tube. The samples were treated by adding eight volumes of 0.05% dithiothreitol (Sputolysin; Calbiochem Corp; San Diego, CA) in Dulbecco phosphatebuffered saline solution. One volume of protease inhibitors (0.1 mol/l ethylenediaminetetraacetic acid and 2 mg/ml phenylmethylsulfonylfluoride) was added to 100 volumes of the homogenized sputum, and the total cell count was determined with a hemocytometer. The homogenized sputum was spun in a cytocentrifuge, and 500 cells were read on each stained (Diff-Quick solution; American Scientific Products; Chicago, IL) sputum slide. Allergy Skin Prick Tests Responders (n 46) Nonresponders (n 40) Severity, moderate/severe Moderate Severe Age, yr FEV 1, % predicted FEV 1 /FVC ratio FEF 25 75%,% Atopy, % Duration of asthma, yr Smoking history, pack-yr Blood eosinophils, % Sputum eosinophils, % AQLQ Total IgE, unit *Values given as mean SD or No., unless otherwise indicated. 12%. 12%. p 0.05 compared with responder asthma patients. Allergy skin prick tests were performed using commercially available inhalant allergens, which included dust mites (Dermatophagoides farinae and Dermatophagoides pteronyssinus; Bencard Co; Brentford, UK) and histamine (1 mg/ml). None of the subjects had received antihistamines orally in the 3 days preceding the study. All of the tests included positive controls (1 mg/ml histamine) and negative controls (diluent). After 15 min, the mean diameters of the wheals formed by the allergens were compared with those formed by histamine. If the former was the same or larger than the latter (allergen/histamine ratio, 1.0), the reaction was deemed to be positive. Atopy was determined by the presence of an immediate skin reaction to one or more aeroallergens, as described previously. 14 Statistical Analysis The data were double-entered into a statistical software package (SPSS, version 10.0; SPSS Inc; Chicago, IL). The data are expressed as the mean SD. Comparisons of continuous variables for responder and nonresponder patients with asthma were made using independent sample t testing. Differences in the proportions of patient populations were analyzed by 2 testing with the Fisher exact test when low expected cell counts were encountered. Multivariate logistic regression analysis with a step-wise selection method at p 0.05 for entry into the model was used to obtain the independent effects of factors showing significant associations with responsiveness to inhaled GC therapy. A p 0.05 was considered to be statistically significant. Results Of the 86 patients in the study, 79 patients (91.8%) were followed up at 4 weeks. Seven asthmatic patients who were included as nonresponders had moved to the combination or add-on therapy, owing to decreases of 12% in FEV 1 or AQLQ, with symptom aggravation. A total of 79 asthmatic patients finished the study by continuing the inhaled GC therapy for 4 weeks. The mean overall compliance and accuracy rates were % and %, respectively. During the study period, 46 patients (53.4%) with asthma showed a 12% increase in FEV 1 in response to high-dose inhaled GC therapy, and 40 patients were nonresponders (Table 1). For 17 of the nonresponders, the FEV 1 values were decreased compared with the baseline levels. There was no difference in mean baseline FEV 1 levels between responders and the group receiving combination or add-on therapy with symptom aggravation ( % vs %, respectively) [Table 1]. The change in FEV 1 ( FEV 1 [FEV 1 at 4 weeks baseline FEV 1 ]/baseline FEV 1 100) following the inhalation of GCs varied from 21 to 126.8% (Fig 2). The change in FVC ( FVC [FVC at 4 weeks baseline FVC]/ baseline FVC 100) following the inhalation of GCs ranged from 20 to 47%. The change in forced expiratory flow (FEF) [ FEF (FEF at 4 weeks baseline FEF)/baseline FEF 100] following the inhalation of GCs ranged from 55.1 to 95%. The mean values for FEV 1 percent predicted, FEF 25 75%, FEV 1 /FVC ratio, and AQLQ score were 1142 Clinical Investigations
4 positively with the proportions of sputum eosinophils (r 0.242; p 0.05) prior to the inhaled GC treatment. AHR prior to the inhaled GC treatment was not associated with responsiveness to inhaled GCs. In a multiple logistic regression model that included all of the patients and that was adjusted for age, sex, atopy, AQLQ score, asthma duration, number of cigarette pack-years smoked, blood eosinophil count, and sputum eosinophil count, the FEV 1 percent predicted values prior to treatment were independently associated with responsiveness to inhaled GC therapy (odds ratio, 1.126; 95% confidence interval, to 1.228; p 0.007). Figure 2. Change in FEV 1 following glucocorticoid inhalation therapy for 4 weeks. significantly increased from baseline values after 4 weeks of GC inhalation therapy (FEV 1, % vs % predicted, respectively; FEF 25 75%, % vs %, respectively; FEV 1 / FVC ratio, % vs %, respectively; and AQLQ, % vs %, respectively; p 0.01). The FEV 1 percent predicted, FEF 25 75%, FEV 1 /FVC ratio, and AQLQ score were also significantly increased after 4 weeks of inhaled GC therapy in patients who were classified as having moderate-to-severe asthma (Table 2). The pretreatment values for FEV 1, FVC, FEV 1 /FVC, and FEF 25 75% were significantly lower in responder patients than in nonresponder patients (Table 1). The responder patients exhibited higher response rates to inhaled, shortacting bronchodilators than did nonresponder patients with asthma (48.3% [15 of 31 patients] vs 26.4% [9 of 34 patients], respectively; p 0.05). The responder asthmatic patients with FEV 1 values of 12% had significantly higher proportions of blood eosinophils and lower baseline FEV 1 values. The FEV 1 values correlated negatively with the FEV 1 percent predicted and FEF 25 75% values (r and p vs r and p 0.05, respectively) and correlated Table 2 Percentage of Change in AQLQ Score and Spirometry Following GC Inhalation Therapy for 4 Weeks Compared with Baseline Values Prior to Treatment* Variables Moderate Asthma (n 55) Severe Asthma (n 31) Mean SD p Value Mean SD p Value AQLQ FEV 1% predicted FEV 1 /FVC FEF 25 75% *Plus-minus values are mean SD. Discussion Our findings provide additional insight into the response of asthmatic patients to high-dose inhaled GC therapy. Among the patients with asthma, we found diverse associations with the FEV 1 changes following 4 weeks of GC inhalation therapy. Higher blood and sputum eosinophil levels and lower FEV 1 values prior to treatment play important roles in the responsiveness to inhaled GC therapy of patients with moderate-to-severe asthma. GCs, which are usually administered by inhalation, are potent inhibitors of inflammatory responses and are currently considered to be the standard therapeutic regimen for the treatment of persistent asthma. 8 GC therapy reduces the number of infiltrating eosinophils and lymphocytes in the airways of asthmatic patients, and decreases the production and release of proinflammatory mediators and cytokines. As a consequence, some of the structural abnormalities of asthmatic airways are normalized after GC treatment. 15 In our study, asthmatic patients who were responders had higher levels of blood eosinophils and sputum eosinophils prior to GC inhalation, which indicates that asthmatic patients with eosinophilic airway inflammation are more responsive to inhaled GC therapy. An earlier 5-month clinical study of inhaled beclomethasone propionate (BDP) examined 156 patients with asthma; despite increasing doses of inhaled BDP (from 400 to 1,600 g), which were delivered via a pressurized, metered dose inhaler, no additional benefits in terms of FEV 1 were derived from the treatment. 16 However, later studies showed a good dose-response relationship. The control of asthma was superior in patients who received high doses of BDP (1,000 to 2,000 g/d) to that in patients who received the lower dose (400 g/d). 21 Similar results were observed for patients who received FP. 22,23 However, these dose-response studies failed to show statistically significant differences CHEST / 128 / 3/ SEPTEMBER,
5 between the clinical effects of adjacent doses within the dose-response curve. Normally, a difference of fourfold or more in dosage has been required to detect a statistically significant (and often small) difference in commonly measured outcomes, such as symptoms, peak expiratory flow, use of rescue 2 - agonist, and lung functions. Changes in the PC 20 for methacholine, which is a more sensitive parameter, have shown the dose-response effects of budesonide (200 vs 800 g/d, respectively). 24 In the present study, we evaluated the effect of high-dose inhaled GC therapy in order to exclude the dose-dependent effect of GCs. We found significant increases in FEV 1 at 4 weeks in asthmatic patients who had received high doses of inhaled GCs. Patient responsiveness to inhaled GC therapy varied widely, and we examined the factors associated with these variations. FEV 1, sputum eosinophil numbers, blood eosinophil numbers, and the responses to bronchodilators prior to receiving inhaled GC therapy were associated with the responsiveness to inhaled GC therapy. Despite the use of high-dose inhaled GC therapy, some patients are unable to dispense with oral GC therapy. 25 However, high doses of inhaled steroids can effectively replace oral steroids in 70 to 90% of patients. It is now well-documented, in both adults and children, that long-term treatment with inhaled GC therapy suppresses the disease by affecting the underlying airway inflammation. As a result, the symptoms disappear and the lung function improves. The outcome parameter that responds most rapidly to the initiation of inhaled steroid therapy is that of symptoms; peak expiratory flow values improve gradually, whereas improvements in AHR may continue over many months or even years. Inhaled GC therapy may also modify the disease outcome if it is prescribed early enough and for a long enough period. However, if inhaled steroid therapy is stopped, most patients eventually reexperience the symptoms of asthma. The speed of relapse is probably related to patient age, length of symptom history, severity of symptoms, and duration of treatment. In our study, FEV 1 was significantly increased following 4 weeks of GC inhalation therapy, which underlines the importance of the number of blood eosinophils and sputum eosinophils over other factors, such as age, duration of asthma, atopy, and PC 20 for methacholine. The long-term follow-up of AHR, such as with PC 20 for methacholine measurements, is needed for verification. Nonresponders to inhaled GC therapy tended to be older and to have had asthma longer, which suggests that age and longer asthma duration may cause airway remodeling, thereby making the airways less responsive to inhaled GC therapy. The responder asthmatic patients had higher response rates to short-acting bronchodilators prior to the GC inhalation treatment, which indicates that the tone of the airway smooth muscles is a crucial factor in determining the effectiveness of inhaled GC therapy. Active cigarette smoking is common in adult patients with asthma, with 20% being current smokers. 26,27 Current smokers with asthma, compared with neversmokers, have more severe asthma symptoms. Cigarette smoking impairs the efficacy of corticosteroid therapy in subjects with asthma. 28 In our study, although 19 patients with asthma were current smokers, and patients with severe asthma had a history of more pack-years of smoking, there were no differences in the therapeutic response to GCs. An intriguing question that remains to be answered concerns the significance that should be attached to the lack of responsiveness to inhaled GC therapy. Changes in GC receptors, abnormalities in the binding to GC receptors, and alterations in the translocation to (transcription factor modulating and) GC-responsive genes are all known mechanisms of GC insensitivity A total of 15 missense, 3 nonsense, 3 frameshift, 1 splice site, and 2 alternative spliced mutations have been reported in the NR3C1 gene associated with GC resistance, as well as in 16 polymorphisms. 32 Additional study will elucidate the association between genetic differences and variable responsiveness to inhaled steroids. In addition, studies that address the mechanisms of different airway responses to inhaled GC therapy will be important for establishing the best management strategies for asthma. References 1 Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332: Kamada AK, Szefler SJ, Martin RJ, et al. Issues in the use of inhaled glucocorticoids: The Asthma Clinical Research Network. Am J Respir Crit Care Med 1996; 153: National Asthma Education and Prevention Program. National Asthma Education and Prevention Program: expert panel report; guidelines for the diagnosis and management of asthma update on selected topics J Allergy Clin Immunol 2002; 110:S141 S219 4 Ward C, Pais M, Bish R, et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002; 57: Toogood JH. High-dose inhaled steroid therapy for asthma. J Allergy Clin Immunol 1989; 83: Lim S, Jatakanon A, John M, et al. Effect of inhaled budesonide on lung function and airway inflammation: assessment by various inflammatory markers in mild asthma. Am J Respir Crit Care Med 1999; 159: Amirav I, Goren A, Pawlowski NA. What do pediatricians in training know about the correct use of inhalers and spacer devices? J Allergy Clin Immunol 1994; 94: American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev 1144 Clinical Investigations
6 Respir Dis 1991; 144: American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma: this official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November Am Rev Respir Dis 1987; 136: Juniper EF, Guyatt GH, William A, et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47: Junifer EF, Cockcroft DW, Hargreave FE, et al. Histamine and methacholine inhalation tests: a laboratory tidal breathing protocol. 2nd ed. Lund, Sweden: Astra Draco, Norzila MZ, Fakes K, Henry RL, et al. Interleukin-8 secretion and neutrophil recruitment accompanies induced sputum eosinophil activation in children with acute asthma. Am J Respir Crit Care Med 2000; 161: Pizzichini MM, Pizzichini E, Clelland L, et al. Sputum in severe exacerbation of asthma: kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med 1997; 155: Park CS, Kim YY, Kang SY. Collection between RAST and skin test for inhalant offending allergens. J Korean Soc Allergol 1983; 3: Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist terbutaline on airway inflammation in newly diagnosed asthma: a randomized, double-blind parallel group controlled trial. J Allergy Clin Immunol 1992; 90: Laitinen LA, Laitinen A, Heino M, et al. Eosinophilic airway inflammation during exacerbation of asthma and its treatment with inhaled corticosteroid. Am Rev Respir Dis 1991; 143: Toogood JH, Baskerville JC, Jennings B, et al. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J Allergy Clin Immunol 1982; 70: Laursen LC, Taudorf E, Weeke B. High-dose inhaled budesonide in treatment of severe steroid-dependent asthma. Eur J Respir Dis 1986; 68: Busse WW, Sedgwick JB, Jarjour NN, et al. Eosinophils and basophils in allergic airway inflammation. J Allergy Clin Immunol 1994; 94: Shapiro GG. Steroids and asthma. Pediatrics 1995; 96: Smith MJ, Hodson ME. High-dose beclomethasone inhaler in the treatment of asthma. Lancet 1983; 1: Wasserman SI, Gross GN, Schoenwetter WF, et al. A 12- week dose-ranging study of fluticasone propionate powder in the treatment of asthma. J Asthma 1996; 33: Wolfe JD, Selner JC, Mendelson LM, et al. Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study. Clin Ther 1996; 8: Kraan J, Koeter GH, van der Mark TW, et al. Dosage and time effects of inhaled budesonide on bronchial hyperreactivity. Am Rev Respir Dis 1988; 137: Noonan M, Chervinsky P, Busse WW, et al. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 1995; 152: Althuis MD, Sexton M, Prybylski D. Cigarette smoking and asthma symptom severity among adult asthmatics. J Asthma 1999; 36: Siroux V, Pin I, Oryszczyn MP, et al. Relationships of active smoking to asthma and asthma severity in the EGEA study. Eur Respir J 2000; 15: Chaudhuri R, Livingston E, McMahon AD, et al. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003; 168: Kraft M, Vianna E, Martin RJ, et al. Nocturnal asthma is associated with reduced glucocorticoid receptor binding affinity and decreased steroid responsiveness at night. J Allergy Clin Immunol 1999; 103: Gagliardo R, Chanez P, Vignola AM, et al. Glucocorticoid receptor and in glucocorticoid dependent asthma. Am J Respir Crit Care Med 2000; 162: Sher ER, Leung DYM, Surs W, et al. Steroid resistant asthma: cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994; 93: Bray PJ, Cotton RG. Variations of the human glucocorticoid receptor gene (NR3C1): pathological and in vitro mutations and polymorphisms. Hum Mutat 2003; 21: CHEST / 128 / 3/ SEPTEMBER,
The Impact of Smoking on Clinical and Therapeutic Effects in Asthmatics
J Korean Med Sci 2009; 24: 209-14 ISSN 1011-8934 DOI: 10.3346/jkms.2009.24.2.209 Copyright The Korean Academy of Medical Sciences The Impact of Smoking on Clinical and Therapeutic Effects in Asthmatics
More informationEffects of Smoking Cessation on Airflow Obstruction and Quality of Life in Asthmatic Smokers
Original Article Allergy Asthma Immunol Res. 1 October;2(4):254-259. doi: 1.4168/aair.1.2.4.254 pissn 92-7355 eissn 92-7363 Effects of Smoking Cessation on Airflow Obstruction and Quality of Life in Asthmatic
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationDo current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma?
Respiratory Medicine (2006) 100, 458 462 Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma? Haim S. Bibi a,, David Feigenbaum a, Mariana Hessen
More informationComparison of the Effect of Short Course of Oral Prednisone in Patients with Acute Asthma
ISPUB.COM The Internet Journal of Pulmonary Medicine Volume 7 Number 1 Comparison of the Effect of Short Course of Oral Prednisone in Patients with Acute Asthma E Razi, G Moosavi Citation E Razi, G Moosavi.
More informationDiagnosis, Treatment and Management of Asthma
Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.
More informationBudesonide treatment of moderate and severe asthma in children: A doseresponse
Budesonide treatment of moderate and severe asthma in children: A doseresponse study Soren Pedersen, MD, PhD, and Ove Ramsgaard Hansen, MD Kolding, Denmark Objective: The purpose of the study was to evaluate
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationKey words: airway hyperreactivity; asthma; eosinophilic bronchitis; interleukin-5; interleukin-13
Interleukin-13 and Interleukin-5 in Induced Sputum of Eosinophilic Bronchitis* Comparison With Asthma Sung-Woo Park, MD, PhD; Hee Kyung Jangm MS; Mi Hyoun An, MS; Ji Won Min, MS; An-Soo Jang, MD, PhD;
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationImpact of Asthma in the U.S. per Year. Asthma Epidemiology and Pathophysiology. Risk Factors for Asthma. Childhood Asthma Costs of Asthma
American Association for Respiratory Care Asthma Educator Certification Prep Course Asthma Epidemiology and Pathophysiology Robert C. Cohn, MD, FAARC MetroHealth Medical Center Cleveland, OH Impact of
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationThe FDA Critical Path Initiative
The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary
More informationBUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
More informationExhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma
Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Jason Debley, MD, MPH Assistant Professor, Pediatrics Division of Pulmonary Medicine University of Washington School of
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationC linicians have long regarded asthma as a heterogeneous
875 ORIGINAL ARTICLE Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids R H Green, C E Brightling,
More informationCOPD or not COPD, that is the question.
COPD or not COPD, that is the question. Asthma-COPD Overlap Syndrome: ACOS Do we really need this? Michelle Harkins Disclosure Slide Slide help - William Busse, MD Organizational Interests ATS, ACCP, ACP
More informationYoung Yoo, MD; Jinho Yu, MD; Do Kyun Kim, MD; and Young Yull Koh, MD
Original Research ASTHMA Percentage Fall in FVC at the Provocative Concentration of Methacholine Causing a 20% Fall in FEV 1 in Symptomatic Asthma and Clinical Remission During Adolescence* Young Yoo,
More informationInternational Journal of Medical Research & Health Sciences
International Journal of Medical Research & Health Sciences www.ijmrhs.com Volume 2 Issue 3 July - Sep Coden: IJMRHS Copyright @2013 ISSN: 2319-5886 Received: 23 th May 2013 Revised: 24 th Jun 2013 Accepted:
More informationDual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.
DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms
More informationBenzalkonium Chloride Induced Bronchoconstriction in Patients with Stable Bronchial Asthma
The Korean Journal of Internal Medicine : 22:244-248, 2007 Benzalkonium Chloride Induced Bronchoconstriction in Patients with Stable Bronchial Asthma Byoung Hoon Lee, M.D. and Sang-Hoon Kim, M.D. Department
More informationCurrent Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationAbstract Background Theophylline is widely used in the treatment of asthma, and there is evidence that theophylline has antiinflammatory
Thorax 2000;55:837 841 837 National Heart and Lung Institute, Imperial College School of Medicine and Royal Brompton Hospital, London SW3 6LY, UK S Lim A Jatakanon K F Chung P J Barnes Napp Laboratories
More informationOnline Data Supplement. Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey
Online Data Supplement Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey Dong Soon Kim, MD, Young Sam Kim MD, Kee Suk Chung MD, Jung Hyun Chang
More informationW e have shown in a previous meta-analysis of placebo
16 ASTHMA Clinical dose-response relationship of fluticasone propionate in adults with asthma M Masoli, M Weatherall, S Holt, R Beasley... See end of article for authors affiliations... Correspondence
More informationMethacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges
Methacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges AAAAI San Antonio Tx February 2013 Catherine Lemière MD, MSc Hôpital du
More informationAirways hyperresponsiveness to different inhaled combination therapies in adolescent asthmatics
Airways hyperresponsiveness to different inhaled combination therapies in adolescent asthmatics Daniel Machado 1, MD Celso Pereira 1,2, MD, PhD Beatriz Tavares 1, MD Graça Loureiro 1, MD António Segorbe-Luís
More informationAsthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
More informationNON-SPECIFIC BRONCHIAL HYPERESPONSIVENESS. J. Sastre. Allergy Service
NON-SPECIFIC BRONCHIAL HYPERESPONSIVENESS J. Sastre. Allergy Service Asthma: definition Asthma is a syndrome defined on basis of three main aspects: 1- Symptoms due to variable and reversible airway obstruction
More informationAsthma is a heterogeneous airway disease. Identification of asthma clusters in two independent Korean adult asthma cohorts
Eur Respir J 2013; 41: 1308 1314 DOI: 10.1183/09031936.00100811 CopyrightßERS 2013 Identification of asthma clusters in two independent Korean adult asthma cohorts Tae-Bum Kim*,"", An-Soo Jang #,"", Hyouk-Soo
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationMeeting the Challenges of Asthma
Presenter Disclosure Information 11:05 11:45am Meeting the Challenge of Asthma SPEAKER Christopher Fanta, MD The following relationships exist related to this presentation: Christopher Fanta, MD: No financial
More informationMeenu Singh, Joseph L. Mathew, Prabhjot Malhi, B.R. Srinivas and Lata Kumar
Comparison of Improvement in Quality of Life Score with Objective Parameters of Pulmonary Function in Indian Asthmatic Children Receiving Inhaled Corticosteroid Therapy Meenu Singh, Joseph L. Mathew, Prabhjot
More informationLow- and high-dose fluticasone propionate in asthma; effects during and after treatment
Eur Respir J 2000; 15: 11±18 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 2000 European Respiratory Journal ISSN 0903-1936 Low- and high-dose fluticasone propionate in asthma; effects
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationAirwayin ammationinasthmawithincomplete reversibility of air ow obstruction $
Vol. 97 (2003) 739^744 Airwayin ammationinasthmawithincomplete reversibility of air ow obstruction $ L-P. BOULET*, H.TURCOTTE,O.TURCOT AND J.CHAKIR Ho pitallaval,2725,cheminsainte-foy,sainte-foy,queł bec
More informationPeak Expiratory Flow Variability Adjusted by Forced Expiratory Volume in One Second is a Good Index for Airway Responsiveness in Asthmatics
ORIGINAL ARTICLE Peak Expiratory Flow Variability Adjusted by Forced Expiratory Volume in One Second is a Good Index for Airway Responsiveness in Asthmatics Kazuto Matsunaga, Masae Kanda, Atsushi Hayata,
More informationQ: Should patients with mild asthma
1-MINUTE CONSULT CME CREDIT EDUCATIONAL OBJECTIVE: Readers will consider prescribing inhaled corticosteroids to their patients who have mild persistent asthma brief answers to specific clinical questions
More informationStarting with a Higher Dose of Inhaled Corticosteroids in Primary Care Asthma Treatment
Starting with a Higher Dose of Inhaled Corticosteroids in Primary Care Asthma Treatment THYS van der MOLEN, BETTY MEYBOOM-DE JONG, HELMA H. MULDER, and DIRKJE S. POSTMA Department of General Practice,
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationIncreased Leukotriene E 4 in the Exhaled Breath Condensate of Children With Mild Asthma*
CHEST Original Research Increased Leukotriene E 4 in the Exhaled Breath Condensate of Children With Mild Asthma* Atsushi Shibata, MD; Toshio Katsunuma, MD, PhD; Morimitsu Tomikawa, MD; Aiko Tan, MD; Keisuke
More informationAsthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches
Asthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches William W. Busse,, M.D. University of Wisconsin School of Medicine and Public Health Madison, WI, USA Disclosure Slide Employment
More informationDeterminants of the bronchodilation response to salbutamol on histamine-induced bronchoconstriction
Respiratory Medicine (2006) 100, 1760 1766 Determinants of the bronchodilation response to salbutamol on histamine-induced bronchoconstriction Heikki O. Koskela a,, Vesa Kiviniemi b, Minna K. Purokivi
More informationRespiratory Pharmacology
Allergy Targets of allergies Type I Histamine Leukotrienes Prostaglandins Bradykinin Hypersensitivity reactions Asthma Characterised by Triggered by Intrinsic Extrinsic (allergic) Mediators Result Early
More informationLecture Notes. Chapter 3: Asthma
Lecture Notes Chapter 3: Asthma Objectives Define asthma and status asthmaticus List the potential causes of asthma attacks Describe the effect of asthma attacks on lung function List the clinical features
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationBronchodilator Response in Patients with Persistent Allergic Asthma Could Not Predict Airway Hyperresponsiveness
ORIGINAL ARTICLE Bronchodilator Response in Patients with Persistent Allergic Asthma Could Not Predict Airway Hyperresponsiveness Bojana B. Petanjek, MD, Sanja P. Grle, MD, Dubravka Pelicarić, MD, and
More informationMechanisms of action of bronchial provocation testing
Mechanisms of action of bronchial provocation testing TSANZ / ANZSRS Masterclass: April 3rd, 2016 13:00 13:30 John D. Brannan PhD Scientific Director - Dept. Respiratory & Sleep Medicine John Hunter Hospital,
More information(Asthma) Diagnosis, monitoring and chronic asthma management
Dubai Standards of Care 2018 (Asthma) Diagnosis, monitoring and chronic asthma management Preface Asthma is one of the most common problem dealt with in daily practice. In Dubai, the management of chronic
More informationEvolution of asthma from childhood. Carlos Nunes Center of Allergy and Immunology of Algarve, PT
Evolution of asthma from childhood Carlos Nunes Center of Allergy and Immunology of Algarve, PT allergy@mail.telepac.pt Questionnaire data Symptoms occurring once or several times at follow-up (wheeze,
More informationStep-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.
Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. By: DR MOHD SHAMSUL AMRI Supervisor: Associate Professor Dr
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationAsthma: Chronic Management. Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015
Asthma: Chronic Management Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015 Global Strategy for Asthma Management and Prevention Evidence-based Implementation
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationTolerance to bronchodilating effects of salmeterol in COPD
Respiratory Medicine (2003) 97, 1014 1020 Tolerance to bronchodilating effects of salmeterol in COPD J.F. Donohue a, *, S. Menjoge b, S. Kesten b a University of North Carolina School of Medicine, 130
More informationEffect of inhaled budesonide therapy on lung function in schoolchildren born preterm
RESPIRATORY MEDICINE (2001) 95, 565 570 doi:10.1053/rmed.2001.1104, available online at http://www.idealibrary.com on Effect of inhaled budesonide therapy on lung function in schoolchildren born preterm
More informationCurrent Asthma Therapy: Little Need to Phenotype. Phenotypes of Severe Asthma. Cellular Phenotypes 12/7/2012
Subbasement Membrane Thickness(µm) 12/7/212 Current Asthma Therapy: Little Need to Phenotype Phenotypes of Severe Asthma Most mild and to some degree moderate asthmatics respond well to currently available
More informationIt is well recognized that IgE plays a central role in. Predicting Response to Omalizumab, an Anti-IgE Antibody, in Patients With Allergic Asthma*
Predicting Response to Omalizumab, an Anti-IgE Antibody, in Patients With Allergic Asthma* Jean Bousquet, MD; Sally Wenzel, MD, FCCP; Stephen Holgate, MD; William Lumry, MD; Peter Freeman, PhD; and Howard
More informationEfficacy of a Heat Exchanger Mask in Cold Exercise-Induced Asthma* David A. Beuther, MD; and Richard J. Martin, MD, FCCP
Original Research ASTHMA Efficacy of a Heat Exchanger Mask in Cold Exercise-Induced Asthma* David A. Beuther, MD; and Richard J. Martin, MD, FCCP Study objectives: To determine the efficacy of a novel
More informationAsthma Description. Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways.
Asthma Asthma Description Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways. Symptoms of asthma In susceptible individuals, this inflammation causes recurrent
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationStudy designs and PD/Clinical endpoints to demonstrate therapeutic equivalence: European Views
IPAC-RS/University of Florida Study designs and PD/Clinical endpoints to demonstrate therapeutic equivalence: European Views 20 th March 2014 Dr. Alfredo García - Arieta Head of the Service of Generic
More informationKEY WORDS airflow limitation, airway hyperresponsiveness, airway inflammation, airway lability, peak expiratory flow rate
Allergology International. 2013;62:343-349 DOI: 10.2332 allergolint.13-oa-0543 ORIGINAL ARTICLE Stratifying a Risk for an Increased Variation of Airway Caliber among the Clinically Stable Asthma Atsushi
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationImportance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma
Original Article Importance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma Feng-Jia Chen, Huai Liao, Xin-Yan Huang, Can-Mao Xie Department of Respiratory
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationSergio Bonini. Professor of Internal Medicine, Second University of Naples INMM-CNR, Rome, Italy.
Assessment of EIA in the community and in athletes: the role of standardized questionnaires Sergio Bonini Professor of Internal Medicine, Second University of Naples INMM-CNR, Rome, Italy se.bonini@gmail.com
More informationA comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma
Eur Respir J 1999; 1: 591±596 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 93-1936 A comparison of global questions versus health status questionnaires
More informationChildhood Asthma. The pathophysiology of asthma is an interplay. CME Case Study. Case Study. By Moyez B. Ladhani, MD, CCFP, FAAP, FRCPC
CME Case Study Childhood Asthma By Moyez B. Ladhani, MD, CCFP, FAAP, FRCPC Case Study A two-year-old child presents to your office with a cough, which has been present for three weeks. It is worse at nighttime
More informationAsthma Pathophysiology and Treatment. John R. Holcomb, M.D.
Asthma Pathophysiology and Treatment John R. Holcomb, M.D. Objectives Definition of Asthma Epidemiology and risk factors of Asthma Pathophysiology of Asthma Diagnostics test of Asthma Management of Asthma
More informationBronchial hyperresponsiveness in asthmatic adults A long-term correlation study
European Review for Medical and Pharmacological Sciences 2005; 9: 125-131 Bronchial hyperresponsiveness in asthmatic adults A long-term correlation study R. CARBONE, F. LUPPI *, A. MONSELISE **, G. BOTTINO
More informationThe Asthma Guidelines: Diagnosis and Assessment of Asthma
The Asthma Guidelines: Diagnosis and Assessment of Asthma Christopher H. Fanta, M.D. Partners Asthma Center Brigham and Women s Hospital Harvard Medical School Objectives Know how the diagnosis of asthma
More informationSmall Airways Disease. Respiratory Function In Small Airways And Asthma. Pathophysiologic Changes in the Small Airways of Asthma Patients
Small Airways Disease Respiratory Function In Small Airways And Relevant Questions On Small Airway Involvement In How can small airway disease be defined? What is the link between small airway abnormalities
More informationPerforming a Methacholine Challenge Test
powder for solution, for inhalation Performing a Methacholine Challenge Test Provocholine is a registered trademark of Methapharm Inc. Copyright Methapharm Inc. 2016. All rights reserved. Healthcare professionals
More informationEffect of Inhaled Corticosteroids on Bronchial Hyperresponsiveness in Patients with Mild Asthma
2 3 ai.r. 259 Asian Pacific Journal of Allergy and Immunology (1995) 13 : 81-85 Effect of Inhaled Corticosteroids on Bronchial Hyperresponsiveness in Patients with Mild Asthma Somkiat Wongtim, Somkld Mogmued,
More informationIncreased Releasability of Skin Mast Cells after Exercise in Patients with Exercise-induced Asthma
J Korean Med Sci 4; 19: 724-8 ISSN 11-8934 Copyright The Korean Academy of Medical Sciences Increased Releasability of Skin Mast Cells after Exercise in Patients with Exercise-induced Asthma The role of
More informationChronic Cough Due to Nonasthmatic Eosinophilic Bronchitis. ACCP Evidence-Based Clinical Practice Guidelines
Chronic Cough Due to Nonasthmatic Eosinophilic Bronchitis ACCP Evidence-Based Clinical Practice Guidelines Christopher E. Brightling, MBBS, PhD, FCCP Objectives: Nonasthmatic eosinophilic bronchitis is
More informationEffect of disease duration on dose response of inhaled budesonide in asthma
Respiratory Medicine (2008) 102, 1065 1072 Effect of disease duration on dose response of inhaled budesonide in asthma Olof Selroos a,b, a Mjölbolsta Hospital, Karis, Finland b SEMECO AB, Skogsvägen 5,
More informationIn 2002, it was reported that 72 of 1000
REPORTS Aligning Patient Care and Asthma Treatment Guidelines Eric Cannon, PharmD Abstract This article describes how the National Asthma Education and Prevention Program Guidelines for the Diagnosis and
More informationAsthma and Vocal Cord Dysfunction
Asthma and Vocal Cord Dysfunction Amy L. Marks DO, FACOP Pediatric Allergy and Immunology Assistant Professor of Pediatrics Oakland University William Beaumont School of Medicine Objectives: Understanding
More informationEffects of inhaled versus systemic corticosteroids on exhaled nitric oxide in severe acute asthma
Respiratory Medicine (2009) 103, 614e620 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Effects of inhaled versus systemic corticosteroids on exhaled nitric oxide in
More informationThe New England Journal of Medicine
A COMPARISON OF LOW-DOSE INHALED BUDESONIDE PLUS THEOPHYLLINE AND HIGH-DOSE INHALED BUDESONIDE FOR MODERATE ASTHMA DAVID J. EVANS, M.B., DAVID A. TAYLOR, M.B., OLLE ZETTERSTROM, M.D., K. FAN CHUNG, M.D.,
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationIvax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence
Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence Clinical and cost-effectiveness of QVAR for the treatment of chronic asthma in adults and children
More informationAirway Inflammation in Asthma Chih-Yung Chiu 1,2, Kin-Sun Wong 2 1 Department of Pediatrics, Chang Gung Memorial Hospital, Keelung, Taiwan.
REVIEW ARTICLE Chih-Yung Chiu 1,2, Kin-Sun Wong 2 1 Department of Pediatrics, Chang Gung Memorial Hospital, Keelung, Taiwan. 2 Division of Pediatric Pulmonology, Department of Pediatrics, Chang Gung Memorial
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationPathology of Asthma Epidemiology
Asthma A Presentation on Asthma Management and Prevention What Is Asthma? A chronic disease of the airways that may cause Wheezing Breathlessness Chest tightness Nighttime or early morning coughing Pathology
More informationControversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Stanley J. Szefler, MD Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head, Pediatric
More informationValidity and Reliability of CAT and Dyspnea-12 in Bronchiectasis and Tuberculous Destroyed Lung
http://dx.doi.org/10.4046/trd.2012.72.6.467 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2012;72:467-474 CopyrightC2012. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights
More informationNew Therapies for Asthma
New Therapies for Asthma Tracy Bridges, MD Speaker Disclosure: Dr. Bridges participates in speaker bureaus for Teva, Genetech & Astra Zeneca. Objectives: Discuss the use of LAMA s for Asthma Detail the
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback
More informationIs reslizumab effective in improving quality of life and asthma control in adolescent and adult patients with poorly controlled eosinophilic asthma?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is reslizumab effective in improving
More informationBreakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom
Breakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom 2 BEYOND SYMPTOMS ADDRESSING FUTURE RISK IN ASTHMA South GP CME 2013,
More informationClinical and Radiologic Features, Lung Function, and Airway Inflammation
Original Research SMOKING Smoking and Asthma* Clinical and Radiologic Features, Lung Function, and Airway Inflammation Louis-Philippe Boulet, MD; Catherine Lemière, MD; Francine Archambault, MD; Guy Carrier,
More information